Skip to main content

dostarlimab (Jemperli®)

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria dostarlimab (Jemperli®) can be made available within NHS Wales for the first-line treatment of locally advanced stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer. This recommendation applies only in circumstances where the approved commercial arrangement price is applied.

The risks and benefits of the off-label use of dostarlimab (Jemperli®) for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with starting and stopping criteria and rationale. Dostarlimab for dMMR_MSI-H rectal cancer. OW26. 2023 (PDF, 186Kb)
 Evidence Status Report. Dostarlimab for dMMR_MSI-H rectal cancer. OW26. 2023 (PDF, 151Kb)

Medicine details

Medicine name dostarlimab (Jemperli®)
Formulation 500 mg concentrate for solution for infusion
Reference number OW26
Indication

First-line treatment of locally advanced stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer

Company GlaxoSmithKline UK
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status One Wales interim decision
Advice number OW26
AWMSG meeting date 11/07/2023
Ratification by Welsh Government 03/08/2023
Date of issue 03/08/2023
Follow AWTTC: